Attributes of High-Value Oncology Practices Identified

Share this content:
Attributes of High-Value Oncology Practices Identified
Attributes of High-Value Oncology Practices Identified

FRIDAY, Nov. 17, 2017 (HealthDay News) -- Attributes that distinguish high-value oncology practices have been identified, according to a study published online Nov. 16 in JAMA Oncology.

Douglas W. Blayney, M.D., from Stanford Cancer Institute in California, and colleagues identified oncology practices with low mean insurer-allowed spending to quantify value. Practices with high quality were selected, and a team conducted site visits to interview practice personnel and probe for attributes of high-value care. Attributes occurring uniquely or frequently in low-spending practices were reviewed for their contribution to value improvement and ease of implementation.

The researchers identified 13 attributes within five themes from the seven practices studied. The themes were: treatment planning and goal setting, services supporting the patient journey, technical support and physical layout, organization and function of the care team, and external context. High-value practice sites were most sharply distinguished by five attributes: conservative use of imaging, early discussion of limitations and consequences of treatment, single point of contact, maximal use of registered nurses for interventions, and a multicomponent health care system. Three attributes -- early and normalized palliative care, ambulatory rapid response, and early discussion of limitations and consequences of treatment -- were judged to have the highest immediate potential for reducing spending without compromising care quality.

"Oncology practice attributes warranting further testing were identified that may lower total spending for high-quality oncology care," the authors write.

One author disclosed ties to Guardant Health Inc.

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »